Retatrutide Research

How One Peptide Engages Three Receptors

UKPWritten & reviewed by The UK Peptides Editorial Team · Research library, UK Peptides2 min readLast reviewed 2026-08-233 cited sources

The short answer

Retatrutide activates the GIP, GLP-1 and glucagon receptors from one sequence. All three are class B G-protein-coupled receptors within the glucagon receptor family, sharing enough structural similarity that a single engineered peptide can engage all three.

Key facts

Receptors
GIPR, GLP-1R, GCGR
Receptor class
Class B GPCRs
Family
Glucagon receptor family
Design
Balanced activity across all three
Scaffold
Modified GIP
Reference
Coskun, Cell Metab 2022

Why three receptors can share one ligand

GIP, GLP-1 and glucagon are related peptide hormones, and their receptors form a structurally related family. That common ancestry means the binding surfaces are similar enough that a sequence can be engineered to satisfy all three, not easily, but possibly. Attempting the same across unrelated receptor families would not be realistic.

Why balance is the hard problem

Similar is not identical. A substitution improving affinity at one receptor frequently reduces it at another, so the design process is a constrained optimisation across three simultaneous requirements rather than three independent ones. Coskun and colleagues describe reaching balanced activity across the three, and that balance is the achievement the paper reports.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £49.99

What each receptor contributes

GLP-1 receptor agonism drives satiety and glucose-dependent insulin secretion. GIP receptor agonism adds effect through mechanisms still debated; the GIP paradox, where both agonism and antagonism appear to help, is unresolved. Glucagon receptor agonism increases energy expenditure and drives hepatic lipid oxidation, offset by the GLP-1 component's glucose-lowering effect.

Why adding glucagon is not self-defeating

Glucagon raises blood glucose, which sounds like the wrong direction. The resolution is that it also increases resting energy expenditure and mobilises hepatic fat, and with sufficient concurrent GLP-1 agonism the glycaemic effect is offset while those remain. Oxyntomodulin, an endogenous GLP-1/glucagon dual agonist, demonstrates that the body already uses this combination.

Why this produces the largest reported effect

More receptors engaged has consistently meant more weight reduction across this field: GLP-1 alone, then GLP-1 plus GIP, then all three. It has also consistently meant more gastrointestinal adverse effects, which is the trade-off the whole class shares. Retatrutide sits at the far end of both.

What remains unsettled

How much each receptor contributes. Because the three activities cannot be separated within one molecule, attributing the observed effect between them requires comparison against compounds engaging fewer receptors. That is what TRIUMPH-5, comparing retatrutide against tirzepatide, is designed to inform.

Frequently asked questions

How can one peptide activate three receptors?
GIPR, GLP-1R and GCGR belong to one structurally related family, so their binding surfaces are similar enough that an engineered sequence can satisfy all three.
Why include glucagon agonism at all?
It raises energy expenditure and mobilises hepatic fat. Sufficient GLP-1 agonism offsets its glucose-raising effect, and oxyntomodulin shows the body uses this combination naturally.
Which receptor contributes most?
Not established. The activities cannot be separated within one molecule, which is part of what a head-to-head against tirzepatide would inform.

Extended research context

The Retatrutide Research deep dive

Deep dive: how the triple-agonist scaffold was engineered

Retatrutide's 39-residue backbone was designed by Eli Lilly's peptide chemistry team to preserve the pharmacophores of three glucagon-family receptors on a single chain. The N-terminal domain retains GIP-receptor contacts, mid-chain substitutions restore GLP-1-receptor affinity lost in native GIP, and additional residue swaps confer glucagon-receptor engagement. A γGlu-2xOEG linker anchors a C20 fatty diacid at Lys17, which reversibly binds serum albumin and slows renal clearance. This is the same albumin-tethering strategy Novo Nordisk pioneered with semaglutide and Lilly refined further in tirzepatide.

The TRIUMPH Phase 3 programme in context

TRIUMPH is Lilly's global Phase 3 development umbrella for retatrutide, spanning obesity (TRIUMPH-1 through TRIUMPH-4), type 2 diabetes, MASH (metabolic dysfunction-associated steatohepatitis), and knee osteoarthritis linked to obesity. Readouts began in 2025 and continue through 2026. Because the compound is investigational, no regulator (FDA, EMA, or MHRA) has issued marketing authorisation, and legitimate supply exists only for laboratory reference and research contexts, never for human administration.

How retatrutide differs from tirzepatide and semaglutide at the mechanism level

Semaglutide is a mono-agonist (GLP-1 only). Tirzepatide is a dual agonist (GIP + GLP-1). Retatrutide adds glucagon-receptor activity, which pre-clinical and Phase 2 data suggest contributes to energy expenditure in addition to appetite regulation and glucose-dependent insulin release. This three-receptor combination is why retatrutide is sometimes called a 'metabolic multi-tool' peptide in the trade press, but the pharmacology is more nuanced than the label implies.

Research applications

  • ▸In vitro receptor-binding assays across GIP-R, GLP-1R and GCGR panels
  • ▸Comparator studies alongside semaglutide, tirzepatide and liraglutide reference standards
  • ▸Analytical-method development: HPLC retention profiling and LC-MS confirmation
  • ▸Stability testing of lipidated 39-residue peptides in aqueous and lyophilised forms
  • ▸Reference material for teaching incretin pharmacology in university-level courses

Handling checklist

  • ✓Store lyophilised vials at −20 °C; protect from light and humidity
  • ✓Reconstitute with bacteriostatic water; avoid vortexing (foams the peptide)
  • ✓Once reconstituted, store at 2–8 °C and use within 28 days
  • ✓Verify batch CoA: HPLC ≥98%, mass matches ~4,731 Da, endotoxin low
  • ✓Do not administer to humans or animals. Research use only

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Confusing retatrutide with tirzepatide in supplier catalogues

Fix: Cross-check the LY code (LY3437943 = retatrutide; LY3298176 = tirzepatide) and the receptor profile on the CoA.

✗ Using tap or filtered water for reconstitution

Fix: Only use bacteriostatic water for injection (0.9% benzyl alcohol) or sterile water, never lab DI water.

✗ Storing reconstituted solution at room temperature

Fix: Refrigerate at 2–8 °C immediately after reconstitution; discard after 28 days.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Related questions researchers ask

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this contentReport a factual error in this article

More Retatrutide Research articles

Popular across the research hub

One flagship guide from every other research category.

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.

← Back to Forum